Search results
Results from the WOW.Com Content Network
[41] c-KIT- and PDGFRA-mutation negative GIST tumors are usually resistant to treatment with imatinib, [16] as is neurofibromatosis-1-associated wild-type GIST. [36] A specific subtype of PDGFRA mutation, D842V, is also insensitive to imatinib. [36] [42] Recently, in PDGFRA-mutated GIST, avapritinib has been approved by FDA. [43]
Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.
The prognosis for these types of tumors depends heavily on the size of the tumor and the rate of mitosis, however approximately 60 percent of GISTs are diagnosed as benign. [4] Surgery to remove the tumor is the primary treatment method, although imatinib, everolimus, and rapamycin may soon be approved as alternative treatment and management ...
The TNM Classification of Malignant Tumors (TNM) is a globally recognised standard for classifying the anatomical extent of the spread of malignant tumours (cancer). It has gained wide international acceptance for many solid tumor cancers, but is not applicable to leukaemia or tumors of the central nervous system. Most common tumors have their ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
Transarterial bland embolization (TAE, also known as HAE) is a catheter-based tumor treatment of the liver.In this procedure, embolizing agents (e.g., polyvinyl alcohol, gelfoam, acrylic copolymer gelatin particles, embospheres) can be delivered through the tumor's feeding artery in order to completely occlude the tumor's blood supply.
CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of: CHOP consists of: C yclophosphamide , an alkylating agent which damages DNA by binding to it and causing the formation of cross-links
Cancer specific T-cells can be obtained by fragmentation and isolation of tumor infiltrating lymphocytes, or by genetically engineering cells from peripheral blood. The cells are activated and grown prior to transfusion into the recipient (tumor bearer).